Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Tissue Plasminogen Activator(Archived)

Talha N. Jilani  1 , Abdul H. Siddiqui  2
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan.
.
Affiliations
Free Books & Documents
Book

Tissue Plasminogen Activator(Archived)

Talha N. Jilani et al.
Free Books & Documents

Excerpt

Tissue plasminogen activator (tPA) is classified as a serine protease (an enzyme that cleaves peptide bonds in proteins). It is thus 1 of the essential components of blood clot dissolution. Its primary function includes catalyzing the conversion of plasminogen to plasmin, the primary enzyme involved in dissolving blood clots. Recombinant biotechnology has enabled the manufacture of tPA in laboratories, and these synthetic products are known as recombinant tissue plasminogen activators (rt-PA). These drugs have undergone various modifications to amplify their pharmacokinetics and pharmacodynamics, particularly by prolonging their short half-life in circulation and increasing their fibrin specificity to prevent an unwanted fibrinolytic state. Examples of these drugs include alteplase, reteplase, and tenecteplase. Indications for the use of tPA include the following:

PubMed Disclaimer

Conflict of interest statement

Disclosure: Talha Jilani declares no relevant financial relationships with ineligible companies.

Disclosure: Abdul Siddiqui declares no relevant financial relationships with ineligible companies.

References

    1. Gravanis I, Tsirka SE. Tissue-type plasminogen activator as a therapeutic target in stroke. Expert Opin Ther Targets. 2008 Feb;12(2):159-70. - PMC - PubMed
    1. Heiferman DM, Li DD, Pecoraro NC, Smolenski AM, Tsimpas A, Ashley WW. Intra-Arterial Alteplase Thrombolysis during Mechanical Thrombectomy for Acute Ischemic Stroke. J Stroke Cerebrovasc Dis. 2017 Dec;26(12):3004-3008. - PubMed
    1. Rogers SD, Riemersma LB, Clements SD. Tissue plasminogen activator: an evaluation of clinical efficacy in acute myocardial infarction. Pharmacotherapy. 1987;7(4):111-21. - PubMed
    1. Niedermeyer J, Meissner E, Fabel H. [Thrombolytic therapy in pulmonary embolism. Indications and therapeutic strategies]. Z Gesamte Inn Med. 1993 Jun-Jul;48(6-7):332-43. - PubMed
    1. Sharifi M, Bay C, Nowroozi S, Bentz S, Valeros G, Memari S. Catheter-directed thrombolysis with argatroban and tPA for massive iliac and femoropopliteal vein thrombosis. Cardiovasc Intervent Radiol. 2013 Dec;36(6):1586-1590. - PubMed

Publication types

LinkOut - more resources